64,952 Shares in Biogen Inc. $BIIB Bought by Contrarius Group Holdings Ltd

Contrarius Group Holdings Ltd acquired a new stake in Biogen Inc. (NASDAQ:BIIB) in the 4th quarter, HoldingsChannel reports. The fund acquired 64,952 shares of the biotechnology company’s stock, valued at approximately $11,431,000. Biogen makes up 0.6% of Contrarius Group Holdings Ltd’s investment portfolio, making the stock its 25th largest holding.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Rothschild Investment LLC boosted its position in Biogen by 12.3% in the 4th quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company’s stock worth $90,000 after purchasing an additional 56 shares in the last quarter. Advisory Services Network LLC grew its position in Biogen by 3.9% during the third quarter. Advisory Services Network LLC now owns 1,792 shares of the biotechnology company’s stock valued at $251,000 after buying an additional 68 shares during the period. Davis Investment Partners LLC grew its position in Biogen by 1.7% during the fourth quarter. Davis Investment Partners LLC now owns 4,374 shares of the biotechnology company’s stock valued at $778,000 after buying an additional 71 shares during the period. Optas LLC grew its position in Biogen by 4.5% during the fourth quarter. Optas LLC now owns 1,706 shares of the biotechnology company’s stock valued at $300,000 after buying an additional 73 shares during the period. Finally, Parallel Advisors LLC grew its position in Biogen by 1.9% during the fourth quarter. Parallel Advisors LLC now owns 4,302 shares of the biotechnology company’s stock valued at $757,000 after buying an additional 79 shares during the period. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen Price Performance

Shares of NASDAQ BIIB opened at $195.34 on Monday. The firm has a 50-day simple moving average of $187.60 and a 200-day simple moving average of $183.46. The stock has a market capitalization of $28.84 billion, a price-to-earnings ratio of 20.96 and a beta of 0.20. The company has a quick ratio of 2.41, a current ratio of 3.06 and a debt-to-equity ratio of 0.34. Biogen Inc. has a 52 week low of $121.05 and a 52 week high of $205.97.

Biogen (NASDAQ:BIIB) last issued its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, beating analysts’ consensus estimates of $2.95 by $0.62. The business had revenue of $2.48 billion during the quarter, compared to analysts’ expectations of $2.29 billion. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same period in the prior year, the business earned $3.02 earnings per share. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, equities analysts predict that Biogen Inc. will post 14.18 earnings per share for the current fiscal year.

Key Headlines Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen’s salanersen won FDA Breakthrough Therapy Designation for SMA, with early phase 1b data suggesting meaningful motor improvements and a once-yearly dosing profile that could make the therapy stand out commercially. BIIB’s Next-Gen SMA Therapy Salanersen Wins FDA’s Breakthrough Tag
• Positive Sentiment: Biogen also highlighted progress on BIIB115 in post-gene therapy SMA, adding to investor optimism that the company has multiple shots on goal in a key neurodegeneration market. Biogen Advances BIIB115 in Post–Gene Therapy SMA: Early Signals for Long‑Term Growth
• Positive Sentiment: Biogen and UCB presented additional data on dapirolizumab pegol in lupus, showing reduced flare rates and lower steroid use, which supports the drug’s potential in a large autoimmune market. UCB and Biogen build steroid-sparing case for lupus drug
• Neutral Sentiment: Biogen is also facing legal overhang after law firms announced investor investigations and fraud-related claims, which could keep sentiment cautious even as pipeline news improves. BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm
• Neutral Sentiment: A separate investor alert from Pomerantz also flagged a claims investigation into Biogen, adding another potential risk factor, though it does not yet indicate any formal enforcement action. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. – BIIB

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. Mizuho lifted their price target on Biogen from $207.00 to $236.00 and gave the company an “outperform” rating in a research note on Tuesday, February 10th. Tudor Pickering set a $201.00 price target on Biogen in a research note on Monday, February 9th. Truist Financial reduced their target price on Biogen from $193.00 to $189.00 and set a “hold” rating for the company in a research note on Monday, April 13th. Evercore began coverage on shares of Biogen in a report on Friday, May 15th. They set an “outperform” rating on the stock. Finally, JPMorgan Chase & Co. increased their price objective on shares of Biogen from $175.00 to $185.00 and gave the company a “neutral” rating in a report on Thursday, April 23rd. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Biogen currently has a consensus rating of “Moderate Buy” and a consensus target price of $215.81.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.